Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2022-12-05 00:00:00 ET · period of report 2022-12-02 · accession 0001209191-22-059702 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-05 | 2022-12-02 | PHIO | Ferrara Robert L | Dir | P - Purchase | $0.41 | +5,000 | 30.0K | +20% | +$2,050 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2022-12-02 | P | A | 5,000 | $0.41 | 30,000 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $0.4075 to $0.4089. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes shares of common stock underlying unvested restricted stock units. |